Wednesday, December 7, 2022, 7:15 PM – 9:15 PM Central Time (8:15 PM – 10:15 PM Eastern Time) – San Antonio, Texas

What Clinicians Want to Know: Addressing Current Questions and Controversies in the Management of HER2-Positive Breast Cancer (Part 1 of a 2-Part Series)

A CME Satellite Symposium Held in Conjunction with the 2022 San Antonio Breast Cancer Symposium®

Location
San Antonio Marriott Rivercenter
101 Bowie St
San Antonio, TX 78205
Hotel Phone: (210) 223-1000

Program Schedule — Central Time
7:00 PM – 7:15 PM — Registration
7:15 PM – 9:15 PM — Dinner Meeting

Meeting Room
Grand Ballroom G-M (3rd floor)


This event will also be webcast live.
Please see Registration tab for details.
There is no registration fee for this event. For the in-person symposium in San Antonio, preregistration is required as seating is limited.  
 
Faculty
Erika Hamilton, MD
Director, Breast and Gynecologic Research Program
Sarah Cannon Research Institute/Tennessee Oncology
Nashville, Tennessee

Sara A Hurvitz, MD
Professor of Medicine
Director, Breast Cancer Clinical Trials Program Division of Hematology-Oncology
David Geffen School of Medicine at UCLA
Medical Director, Clinical Research Unit
Jonsson Comprehensive Cancer Center
Santa Monica, California

Ian E Krop, MD, PhD
Associate Director, Clinical Research
Director, Clinical Trials Office
Chief Clinical Research Officer
Yale Cancer Center
New Haven, Connecticut


Shanu Modi, MD
Member and Attending
Breast Medicine Service
Memorial Sloan Kettering Cancer Center
Professor of Medicine
Weill Cornell Medical College
New York, New York

Sara M Tolaney, MD, MPH
Chief, Division of Breast Oncology
Associate Director, Susan F Smith Center
for Women's Cancers
Senior Physician
Dana-Farber Cancer Institute
Associate Professor of Medicine
Harvard Medical School
Boston, Massachusetts

Moderator
Neil Love, MD
Research To Practice
Miami, Florida


This activity is supported by educational grants from AstraZeneca Pharmaceuticals LP, Daiichi Sankyo Inc, Puma Biotechnology Inc, and Seagen Inc.
Program Schedule — Central Time
7:00 PM – 7:15 PM — Registration
7:15 PM – 9:15 PM — Dinner Meeting

MODULE 1: Optimizing the Management of Localized HER2-Positive Breast Cancer — Dr Tolaney

  • Key clinical factors in the selection of neoadjuvant and adjuvant systemic therapy for HER2-positive localized breast cancer
  • Available data from clinical trials exploring the feasibility of chemotherapy de-escalation in the setting of dual HER2 blockade for localized disease (eg, ADAPT HER2+/HR-, TRAIN-2)
  • Published clinical research findings with the use of postadjuvant neratinib for HER2-positive localized breast cancer
  • Improved rates of CNS recurrence with the use of extended-adjuvant neratinib in the Phase III ExteNET study
  • Clinical and biologic factors (eg, hormonal receptor [HR] status, extent of disease) influencing selection of patients for treatment with postadjuvant neratinib

MODULE 2: Current Considerations in the Treatment of HER2-Positive Metastatic Breast Cancer (mBC) — Dr Krop

  • Clinical factors affecting the selection and sequencing of therapy for patients with HER2-positive mBC (eg, prior HER2-directed therapy, symptomatology, disease-free interval, sites of metastases, HR status)
  • Long-term results, including final overall survival data, from the HER2CLIMB study of tucatinib/trastuzumab/capecitabine for patients with HER2-positive mBC
  • Published findings from key studies (eg, DESTINY-Breast01, DESTINY-Breast02, DESTINY-Breast03) evaluating the use of trastuzumab deruxtecan (T-DXd) for HER2-positive mBC
  • Available efficacy and safety findings from the pivotal NALA study of neratinib/capecitabine for previously treated HER2-positive mBC
  • Optimal integration of tucatinib/trastuzumab/capecitabine, T-DXd and neratinib/capecitabine into therapy for patients with HER2-positive mBC without brain metastases

MODULE 3: Management of HER2-Positive Breast Cancer with CNS Metastases — Dr Hamilton

  • Incidence of CNS metastases in patients with HER2-positive mBC and effect on overall prognosis
  • Appropriate management of HER2-positive disease progression that is limited to the CNS; utility of local strategies
  • Comparative levels of CNS penetration of approved agents for HER2-positive breast cancer
  • CNS activity observed with tucatinib/trastuzumab/capecitabine, T-DXd and neratinib/capecitabine in the pivotal studies leading to their approvals and other recent research efforts (eg, TUXEDO-1) for patients with brain metastases
  • Ongoing clinical trials attempting to further establish the role of novel HER2-directed therapies for patients with brain metastases

MODULE 4: Recent Appreciation of HER2 Low as a Unique Disease Subset; Future Directions in the Management of HER2-Positive and HER2-Low Breast Cancer — Dr Modi

  • Key findings from the Phase III DESTINY-Breast04 trial evaluating T-DXd versus chemotherapy for patients with previously treated HER2-low advanced breast cancer
  • Scientific rationale for ongoing clinical trials (eg, DESTINY-Breast05, CompassHER2 RD) assessing novel HER2-targeted strategies for HER2-positive localized breast cancer; estimated study completion dates
  • Early results with T-DXd-containing neoadjuvant therapy for HER2-low breast cancer
  • Ongoing studies (eg, HER2CLIMB-02, HER2CLIMB-04, HER2CLIMB-05, DESTINY-Breast07, DESTINY-Breast09) attempting to further define the roles of tucatinib and T-DXd in HER2-positive mBC
  • Other promising agents and strategies for localized and advanced HER2-positive and HER2-low breast cancer

MODULE 5: Incidence and Management of Adverse Events Associated with HER2-Targeted Therapy — Dr Hurvitz

  • Frequency and severity of gastrointestinal (GI) side effects (eg, diarrhea, vomiting) with neratinib
  • Dose-escalation and other available approaches to mitigate neratinib-associated GI toxicities
  • Incidence of interstitial lung disease observed with T-DXd; recommendations for monitoring and management
  • Spectrum, incidence, severity and management of other toxicities reported with T-DXd
  • Frequency, severity and management of GI toxicity and other clinically relevant adverse events associated with tucatinib

Target Audience
This activity is intended for medical oncologists, breast surgeons, nurses, radiation oncologists and other healthcare professionals involved in the diagnosis and treatment of breast cancer.

Learning Objectives
Upon completion of this activity, participants should be able to

  • Appreciate the key clinical variables that affect the use of preoperative therapy and the selection of a specific neoadjuvant regimen for patients with HER2-overexpressing localized breast cancer, and integrate this information into treatment decision-making.
  • Evaluate published data to guide the selection and duration of adjuvant and extended-adjuvant therapy for patients with HER2-overexpressing localized breast cancer.
  • Implement a long-term clinical plan for the management of advanced HER2-positive breast cancer, considering recently presented clinical research and incorporating available and recently approved targeted agents and regimens.
  • Design an approach to the care of patients with HER2-positive breast cancer and CNS metastases, evaluating the implications of prior therapeutic exposure, symptomatology and other factors.
  • Recognize common and rare side effects associated with existing and recently approved anti-HER2 agents, and use this information to develop supportive management plans for patients undergoing treatment for HER2-positive breast cancer.
  • Assess ongoing clinical research evaluating novel agents and treatment strategies under development for HER2-positive breast cancer, and counsel patients regarding the potential benefits of trial participation.

CME Credit Form
A CME credit link will be given to each participant at the conclusion of the activity.

Accreditation Statement
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation Statement
Research To Practice designates this live activity for a maximum of 2 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Content Validation and Disclosures
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest will have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

FACULTY — The following faculty reported relevant financial relationships with ineligible entities:

Dr Hamilton — Consulting Agreements (Paid to Institution): Arcus Biosciences, Arvinas, AstraZeneca Pharmaceuticals LP, Black Diamond Therapeutics Inc, Boehringer Ingelheim Pharmaceuticals Inc, CytomX Therapeutics, Daiichi Sankyo Inc, Dantari, Deciphera Pharmaceuticals Inc, Eisai Inc, Genentech, a member of the Roche Group, Greenwich LifeSciences Inc, H3 Biomedicine, iTeos Therapeutics, Janssen Biotech Inc, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, Mersana Therapeutics Inc, Novartis, Orum Therapeutics, Pfizer Inc, Puma Biotechnology Inc, Relay Therapeutics, Seagen Inc, Silverback Therapeutics; Contracted Research (Paid to Institution): AbbVie Inc, Acerta Pharma — A member of the AstraZeneca Group, ADC Therapeutics, Akesobio Australia Pty Ltd, Amgen Inc, ArQule Inc, Arvinas, AstraZeneca Pharmaceuticals LP, Black Diamond Therapeutics Inc, Boehringer Ingelheim Pharmaceuticals Inc, Clovis Oncology, Compugen, Curis Inc, CytomX Therapeutics, Daiichi Sankyo Inc, Dana-Farber Cancer Institute, Deciphera Pharmaceuticals Inc, eFFECTOR Therapeutics Inc, Ellipses Pharma, EMD Serono Inc, Fochon Pharmaceuticals Ltd, FUJIFILM Pharmaceuticals USA Inc, G1 Therapeutics Inc, Genentech, a member of the Roche Group, H3 Biomedicine, Harpoon Therapeutics, Hutchison MediPharma, ImmunoGen Inc, Immunomedics Inc, Incyte Corporation, InventisBio, Jacobio Pharmaceuticals Group Co Ltd, Karyopharm Therapeutics, Leap Therapeutics Inc, Lilly, Lycera, MacroGenics Inc, Marker Therapeutics Inc, Merck, Mersana Therapeutics Inc, Merus BV, Molecular Templates, Myriad Genetic Laboratories Inc, Novartis, NuCana, Olema Oncology, OncoMed Pharmaceuticals Inc, Onconova Therapeutics Inc, ORIC Pharmaceuticals Inc, Orinove Inc, Pfizer Inc, PharmaMar, Pieris Pharmaceuticals Inc, Pionyr Immunotherapeutics, Plexxikon Inc, Puma Biotechnology Inc, Radius Health Inc, Regeneron Pharmaceuticals Inc, Repertoire Immune Medicines, Rgenix, Seagen Inc, Sermonix Pharmaceuticals, Shattuck Labs, Silverback Therapeutics, Stemcentrx, Sutro Biopharma, Syndax Pharmaceuticals Inc, Syros Pharmaceuticals Inc, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc, Tesaro, A GSK Company, Transcenta Holding Ltd, Treadwell Therapeutics, Verastem Inc, Vincerx Pharma, Zenith Epigenetics, Zymeworks Inc. Dr Hurvitz — Contracted Research: Ambrx, Amgen Inc, Arvinas, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Celcuity, CytomX Therapeutics, Daiichi Sankyo Inc, Dantari, Dignitana AB, G1 Therapeutics Inc, Genentech, a member of the Roche Group, Gilead Sciences Inc, GlaxoSmithKline, Greenwich LifeSciences Inc, Lilly, MacroGenics Inc, Novartis, OBI Pharma Inc, Orinove Inc, Orum Therapeutics, Pfizer Inc, Phoenix Molecular Designs, Pieris Pharmaceuticals Inc, Puma Biotechnology Inc, Radius Health Inc, Samumed, Sanofi, Seagen Inc, Stemline Therapeutics Inc, Zymeworks Inc; One-Time Talk: Daiichi Sankyo Inc; Nonrelevant Financial Relationship: Ideal Implant (spouse). Dr Krop — Consulting Agreements: AstraZeneca Pharmaceuticals LP, Daiichi Sankyo Inc, Genentech, a member of the Roche Group, MacroGenics Inc, Seagen Inc; Contracted Research: Genentech, a member of the Roche Group, MacroGenics Inc, Pfizer Inc; Data and Safety Monitoring Board/Committee: Merck, Novartis. Dr Modi — Advisory Committee and Consulting Agreements: AstraZeneca Pharmaceuticals LP, Daiichi Sankyo Inc, Genentech, a member of the Roche Group, Gilead Sciences Inc, MacroGenics Inc, Seagen Inc; Contracted Research (To My Institution): AstraZeneca Pharmaceuticals LP, Daiichi Sankyo Inc, Genentech, a member of the Roche Group, Seagen Inc. Dr Tolaney — Consulting Agreements: 4D Pharma PLC, Aadi Bioscience, ARC Therapeutics, AstraZeneca Pharmaceuticals LP, Athenex, BeyondSpring Pharmaceuticals Inc, Blueprint Medicines, Bristol-Myers Squibb Company, Certara, Chugai Pharmaceutical Co Ltd, CytomX Therapeutics, Daiichi Sankyo Inc, Eisai Inc, Ellipses Pharma, Genentech, a member of the Roche Group, Gilead Sciences Inc, Infinity Pharmaceuticals Inc, Lilly, Menarini Group, Merck, Mersana Therapeutics Inc, Myovant Sciences, Novartis, Odonate Therapeutics, OncoSec Medical, OncXerna Therapeutics Inc, Pfizer Inc, Reveal Genomics, Sanofi, Seagen Inc, Stemline Therapeutics Inc, Umoja Biopharma, Zentalis Pharmaceuticals, Zetagen, Zymeworks Inc; Contracted Research: AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, Cyclacel Pharmaceuticals Inc, Eisai Inc, Exelixis Inc, Genentech, a member of the Roche Group, Gilead Sciences Inc, Lilly, Merck, NanoString Technologies, Nektar, Novartis, Pfizer Inc, Sanofi, Seagen Inc.

MODERATOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: AbbVie Inc, Adaptive Biotechnologies Corporation, ADC Therapeutics, Agios Pharmaceuticals Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, BeyondSpring Pharmaceuticals Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Coherus BioSciences, CTI BioPharma Corp, Daiichi Sankyo Inc, Eisai Inc, Elevation Oncology Inc, EMD Serono Inc, Epizyme Inc, Exact Sciences Corporation, Exelixis Inc, Five Prime Therapeutics Inc, Foundation Medicine, G1 Therapeutics Inc, Genentech, a member of the Roche Group, Genmab, Gilead Sciences Inc, GlaxoSmithKline, Grail Inc, Halozyme Inc, Helsinn Healthcare SA, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Karyopharm Therapeutics, Kite, A Gilead Company, Kronos Bio Inc, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, MEI Pharma Inc, Merck, Mersana Therapeutics Inc, Mirati Therapeutics Inc, Natera Inc, Novartis, Novartis Pharmaceuticals Corporation on behalf of Advanced Accelerator Applications, Novocure Inc, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sanofi, Seagen Inc, Servier Pharmaceuticals LLC, SpringWorks Therapeutics Inc, Sumitomo Dainippon Pharma Oncology Inc, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc, TerSera Therapeutics LLC, Tesaro, A GSK Company, TG Therapeutics Inc, Turning Point Therapeutics Inc, Verastem Inc and Zymeworks Inc.

Research To Practice CME Planning Committee Members, Staff and Reviewers — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.

Supporters
This activity is supported by educational grants from AstraZeneca Pharmaceuticals LP, Daiichi Sankyo Inc, Puma Biotechnology Inc, and Seagen Inc.

San Antonio Marriott Rivercenter
101 Bowie St
San Antonio, TX 78205
Hotel Phone: (210) 223-1000

Meeting Room
Grand Ballroom G-M (3rd floor)

Directions
The Marriott Rivercenter hotel is conveniently located within walking distance (1.5 blocks) of the Henry B González Convention Center, where the 2022 San Antonio Breast Cancer Symposium is taking place.

 
This activity is intended for medical oncologists, breast cancer surgeons, nurses, radiation oncologists and other healthcare professionals involved in the diagnosis and treatment of breast cancer.
​ ​ ​
IN-PERSON registration for clinicians in practice/healthcare professionals
Thank you for your interest in our CME program. At this time online preregistration is closed for this in-person event. SEATS ARE STILL AVAILABLE FOR THE SESSION. Our onsite registration desk will be open at 6:45 PM CT on Wednesday, December 7th. If you are interested in attending, please visit our registration desk outside the Grand Ballroom G-M (third floor) of the Marriott Rivercenter hotel (101 Bowie St), within walking distance of the Henry B Gonzalez Convention Center.

If you have any questions, please feel free to contact us via email at Meetings@ResearchToPractice.com, or call (800) 233-6153.

NOTICE:
Registration for this event is independent of registration for SABCS.

LIVE WEBCAST registration for all professionals

Please note, we will stream this event over Zoom. After registering you will receive a separate confirmation from Zoom with the viewing instructions.

REGISTRATION FOR WEBCAST »

Registration for groups
If you are registering a group (more than 1 person) for this event, please contact us at Meetings@ResearchToPractice.com or (800) 233-6153.
To ensure seating and meal service, please check in at our onsite registration desk 30 minutes before the start of the meeting. We cannot guarantee seating after the start of the program.

Photography and/or video recording may be taken during the educational program by Research To Practice and used in future educational offerings.

Research To Practice fully complies with the legal requirements of the ADA. If you are in need of assistance (ie, physical, dietary, et cetera), please contact us prior to the event at (800) 233-6153.

 

The content of this Open Satellite Event and opinions expressed by presenters are those of the sponsor or presenter and are not of the San Antonio Breast Cancer Symposium.